Related Experiment Video
Updated: Nov 19, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
National Perinatal Hepatitis B Prevention Program: 2009-2017
Alaya Koneru1, Nancy Fenlon2, Sarah Schillie3
1Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention and akoneru@cdc.gov.
Insights
The Perinatal Hepatitis B Prevention Program successfully manages infants born to hepatitis B-positive mothers, increasing identification and post-vaccination testing. Strategies are needed to improve vaccine completion and close identification gaps for hepatitis B prevention.
Area of Science:
- Public Health
- Infectious Diseases
- Immunization Programs
Background:
- Hepatitis B virus (HBV) infection poses a significant public health risk, particularly to infants born to infected mothers.
- The Centers for Disease Control and Prevention's Perinatal Hepatitis B Prevention Program (PHBPP) aims to prevent HBV transmission from mother to infant.
- Effective case management is crucial for ensuring infants receive timely prophylaxis and vaccination.
Purpose of the Study:
- To evaluate trends in programmatic outcomes for infants born to hepatitis B surface antigen (HBsAg)-positive women from 2009 to 2017.
- To assess the effectiveness of the national Perinatal Hepatitis B Prevention Program (PHBPP) in case management and prevention of perinatal HBV transmission.
- To identify areas for improvement in infant identification, vaccination, and serologic testing.
Main Methods:
- Analysis of 2009-2017 annual programmatic reports from 56 US jurisdictions funded by the CDC's PHBPP.
- Assessment of maternal-infant pair characteristics and achievement of infant hepatitis B postexposure prophylaxis, vaccine series completion, and postvaccination serologic testing (PVST).
- Comparison of identified infants with estimated births using race/ethnicity and maternal country of birth methodologies.
Main Results:
- The PHBPP identified 103,825 infants born to HBsAg-positive women between 2009 and 2017.
- The proportion of identified infants increased from 48.1% to 52.6% over the study period.
- Increases were observed in postexposure prophylaxis (94.7% to 97.0%) and PVST (58.8% to 66.8%), while vaccine series completion saw a smaller increase (83.1% to 84.7%).
Conclusions:
- The PHBPP demonstrates success in managing infants born to HBsAg-positive women and promoting hepatitis B immunity.
- Gaps persist between estimated and identified infants, highlighting the need for enhanced surveillance and outreach.
- Further strategies are required to increase vaccine series completion and ensure universal ordering of recommended PVST for all case-managed infants.
Objectives:
To assess trends and programmatic outcomes among infants born to hepatitis B surface antigen (HBsAg)-positive women from 2009 to 2017 and case-managed by the Centers for Disease Control and Prevention's national Perinatal Hepatitis B Prevention Program (PHBPP).
Methods:
We analyzed 2009-2017 annual programmatic reports submitted by 56 US jurisdictions funded through the Centers for Disease Control and Prevention's PHBPP to assess characteristics of maternal-infant pairs and achievement of objectives of infant hepatitis B postexposure prophylaxis, vaccine series completion, and postvaccination serologic testing (PVST). We compared the number of maternal-infant pairs identified by the program with the number estimated born to HBsAg-positive women from 2009 to 2014 and 2015 to 2017 by using a race and/or ethnicity and maternal country of birth methodology, respectively.
Results:
The PHBPP identified 103 825 infants born to HBsAg-positive women from 2009 to 2017, with a range of 10 956 to 12 103 infants annually. Births estimated annually to HBsAg-positive women increased nonsignificantly from 24 804 in 2009 to 26 444 in 2014 (P = .0540) and 20 678 in 2015 to 20 832 in 2017 (P = .8509). The proportion of infants identified annually increased overall from 48.1% to 52.6% (P = .0983). The proportion of case-managed infants receiving postexposure prophylaxis, at least 3 vaccine doses, and PVST increased overall from 94.7% to 97.0% (P = .0952), 83.1% to 84.7% (P = .5377) and 58.8% to 66.8% (P = .0002), respectively.
Conclusions:
The PHBPP has achieved success in managing infants born to HBsAg-positive women and ensuring their immunity to hepatitis B. Nonetheless, strategies are needed to close gaps between the number of infants estimated and identified, increase vaccine series completion, and increase ordering of recommended PVST for all case-managed infants.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Levels of Health Promotion and Illness Prevention
In primary prevention, actions taken before disease onset prevent the disease from...
Preventive Healthcare Services